# Development of a Serum Metabolome-Based Test for Early-Stage Detection of Multiple Cancers

Source: https://onco.cc/key-papers/paper-predomix-metabolome-cancer-rep-2024/  
OnCo record `paper-predomix-metabolome-cancer-rep-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PredOmix, an Indian company, reported that a blood test reading thousands of small molecules by mass spectrometry told 30 cancers from no cancer with about 98% accuracy in 6,445 people; the paper gives few further details.

## Summary

Nagarkar and colleagues (HCG cancer centres with PredOmix Technologies, Gurugram) profiled serum metabolites by untargeted liquid chromatography and high-resolution mass spectrometry and applied the company's machine-learning algorithm in an investigator-initiated trial of 6,445 participants, cancer patients and non-cancer volunteers (CTRI/2023/03/050316). The abstract reports that the platform detected 30 cancers in women and men with an average accuracy of about 98%, and that accuracy did not vary across the four stages. It builds on the company's earlier test for 15 cancers in women (Gupta et al., Scientific Reports 2023).

## Fields

- Kind: Key paper
- Last checked: 2026-11-03
- Journal: Cancer Reports
- Year: 2024
- DOI: 10.1002/cnr2.70042
- Authors: Nagarkar R, Gopichand M, Pal SK, Gupta A, et al.
- Findings: 30 cancers; average accuracy about 98% in 6,445 participants.; Accuracy reported as unchanged across stages I to IV.
- What it means: The abstract gives an average accuracy but no sensitivity at a stated specificity, no numbers of cancers by type or stage and no screening result; accuracy this high in early cancers has not been reproduced by any other multi-cancer test and needs independent confirmation.
- Caveats: Case-control design with known cancers.; No sensitivity, specificity or positive predictive value in the abstract.; Five authors are PredOmix employees and a co-founder holds stock; the work is covered by a patent filing.

## Sources

- Cancer Reports 2024: https://doi.org/10.1002/cnr2.70042
- PubMed: https://pubmed.ncbi.nlm.nih.gov/39559978/
- Gupta et al., Scientific Reports 2023 (15 cancers in women): https://doi.org/10.1038/s41598-023-46553-7

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [OncoVeryx (PredOmix)](https://onco.cc/drugs/oncoveryx/)
- companies: [PredOmix](https://onco.cc/companies/predomix/)
- journals: [Cancer reports](https://onco.cc/journals/cancer-reports/)

---
JSON: https://onco.cc/api/v1/entities/paper-predomix-metabolome-cancer-rep-2024.json